SIRT2 and Sepsis: When used in the acute phase of sepsis, it increases morbidity. When used in the immune hyporesponsive phase of sepsis, it is able to reduce post-sepsis mortality (112).SIRT2 inhibition improves both myeloid and lymphoid immunity and Mtb killing capacity in mouse models (153).